Elkin Estrada, MD
Nephrology · Providence, RINPI 1811995509
Payments from drug & device makers
Across 481 payments — averaging $574.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$152K
- Vertex$116K
- Amgen$1K
- Vifor Pharma, Inc.$863
- Otsuka America Pharmaceutical, Inc.$843
- Bayer$543
- plus $5K from 25 others
What the payments were for
- Food & beverage$10,13196%
- Education$4634%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 88 | $151,583 |
| Vertex | 1 | $116,488 |
| Amgen(2 entities) | 35 | $1,245 |
| Vifor Pharma, Inc. | 58 | $863 |
| Otsuka America Pharmaceutical, Inc. | 41 | $843 |
| Bayer | 25 | $543 |
| GSK | 29 | $470 |
| Calliditas Therapeutics US Inc. | 17 | $454 |
| OPKO Pharmaceuticals, LLC | 25 | $446 |
| Boehringer Ingelheim | 22 | $428 |
| Fresenius USA Marketing, Inc. | 23 | $398 |
| Aurinia Pharma U.S., Inc. | 16 | $390 |
| Akebia Therapeutics Inc | 15 | $379 |
| Travere Therapeutics, Inc. | 20 | $347 |
| Johnson & Johnson | 8 | $234 |
| Ardelyx, Inc. | 9 | $204 |
| Daiichi Sankyo Inc. | 4 | $202 |
| Mallinckrodt Hospital Products Inc. | 9 | $201 |
| Novo Nordisk | 7 | $188 |
| Novartis | 6 | $141 |
| Lexicon Pharmaceuticals, Inc. | 5 | $105 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $94 |
| Ultragenyx Pharmaceutical Inc. | 2 | $41 |
| Arbor Pharmaceuticals, Inc. | 2 | $40 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $38 |
| Shire North American Group Inc | 2 | $32 |
| Alnylam Pharmaceuticals Inc. | 1 | $30 |
| Regeneron Healthcare Solutions, Inc. | 2 | $23 |
| Mallinckrodt Enterprises LLC | 1 | $22 |
| Apellis Pharmaceuticals, Inc. | 1 | $20 |
| Strongbridge US Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$276,503 in reported general payments places this provider in the 90th percentile of 45 nephrology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JynarqueTolvaptan | 13 | $255,855 |
| VelphoroSucroferric Oxyhydroxide | 88 | $174,434 |
| VeltassaPatiromer Calcium Sorbitex | 42 | $34,070 |
| LokelmaSodium Zirconium Cyclosilicate | 49 | $32,396 |
| FarxigaDapagliflozin Propanediol | 29 | $24,509 |
| AuryxiaFerric Citrate | 15 | $16,183 |
| Lanthanum Carbonate | 26 | $15,412 |
| Sevelamer Carbonate | 41 | $7,726 |
| Doxazosin Mesylate | 284 | $4,167 |
| Losartan Potassium | 330 | $3,581 |
| Amlodipine Besylate | 357 | $3,126 |
| Eplerenone | 31 | $2,305 |
| Chlorthalidone | 64 | $1,771 |
| Lisinopril | 177 | $1,572 |
| Hydralazine Hcl | 104 | $1,426 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Jynarque | $843 | $255,85513 claims |
| Fresenius USA Marketing, Inc.Velphoro | $398 | $174,43488 claims |
| AstraZenecaLokelma, Farxiga | $151,583 | $56,90478 claims |
| Akebia Therapeutics IncAuryxia | $379 | $16,18315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 45 nephrology providers in Rhode Island.
Other nephrology in Providence
- Jonah LichtProvidence$207K
- Keith BartolomeiProvidence$93K
- Katherine DavorenProvidence$9K
- Jeffrey ClementProvidence$7K
- Devyani SivakumarProvidence$5K
- Muhammad LiaqatProvidence$4K
- Amol MittalProvidence$3K
- Marc WeinbergProvidence$3K
- Alay NanavatiProvidence$537
- Shijo BenjaminProvidence$491
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.